Screening and analysis of O-glycosylation-associated differential expressed genes in colorectal cancer

doi:10.3969/j.issn.1006-7795.2020.03.016

Abstract

Abstract: Objective To identify differentially expressed genes (DEGs) between normal and abnormal O-glycosylated colon cancer cells, which are regarded as directly O-glycosylation-associated genes, and to investigate their underlying mechanisms. Methods The gene expression profiles of LS174T Tn (+) cells stably transfected with Cosmc or control plasmid were subjected to one-color microarray-based gene expression profiles. After RNA hybridization, gene expression profiles were obtained, and differential and integrative analysis was performed on Wegstalt platform by gene set enrichment analysis (GESA). Gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) tumor-related pathways analysis, R software packages, and protein-protein interaction (PPI) networks by STRING were conducted. Results A total of 1474 genes, including 502 up-regulated genes and 972 down-regulated genes, were selected as DEGs. GO analysis demonstrates that both up-regulated and down-regulated DEGs are enriched for numerous biological processes such as extracellular matrix organization and growth factor activity. DEGs are mainly enriched in several tumor-associated pathways such as phosphatidylinositol 3-kinase (PI3K) signaling pathway, transforming growth factor-β (TGF-β) signaling pathway, and Wnt signaling pathway. Conclusion This study is the first work focused on the transcriptional changes caused by O-glycosylation in colon cancer cells, which helps to uncover the molecular characteristics of O-glycosylated colorectal cancer(CRC) cells and may provide new targets for future research and therapy.

Key words: colorectal cancer, O-glycosylation, gene expression profile, differentially expressed genes, Cosmc, bioinformatics

CLC Number:

R735.3

Yao Jiannan, Gao Tianbo, Duan Ling, Liu Jian, Jiang Yuliang, An Guangyu, Ge Yang. Screening and analysis of O-glycosylation-associated differential expressed genes in colorectal cancer[J]. Journal of Capital Medical University, 2020, 41(3): 403-410.

References

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin,2020, 70(1):7-30.
[2] Wender R C, Brawley O W, Fedewa S A,et al. A blueprint for cancer screening and early detection:Advancing screening's contribution to cancer control[J]. CA Cancer J Clin,2019, 69(1):50-79.
[3] Siegel R L, Jemal A, Wender R C,et al. An assessment of progress in cancer control[J]. CA Cancer J Clin,2018, 68(5):329-339.
[4] Darebna P, Novak P, Kucera R,et al. Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring[J]. J Proteomics,2017, 153:44-52.
[5] Venkitachalam S, Guda K. Altered glycosyltransferases in colorectal cancer[J]. Expert Rev Gastroenterol Hepatol,2017, 11(1):5-7.
[6] Jiang Y, Liu Z, Hu Y,et al. Correlation of Tn antigen expression with mucins in Chinese patients with colorectal cancer[J]. Int J Clin Exp Pathol,2018, 11(3):1562-1568.
[7] Dong X, Jiang Y, Liu J,et al. T-synthase deficiency enhances oncogenic features in human colorectal cancer cells via activation of epithelial-mesenchymal transition[J]. Biomed Res Int,2018, 2018:9532389.
[8] Jiang Y, Liu Z, Xu F,et al. Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer[J]. J Cell Mol Med,2018, 22(10):4875-4885.
[9] Liu Z, Liu J, Dong X,et al. Tn antigen promotes human colorectal cancer metastasis via H-Ras mediated epithelial-mesenchymal transition activation[J]. J Cell Mol Med,2019, 23(3):2083-2092.
[10] Joshi H J, Narimatsu Y, Schjoldager K T,et al. Snapshot:O-glycosylation pathways across kingdoms[J]. Cell,2018, 172(3):632-632.e632.
[11] Tian E, Hoffman M P, Ten Hagen K G.O-glycosylation modulates integrin and FGF signalling by influencing the secretion of basement membrane components[J]. Nat Commun,2012, 3:869.
[12] Park M, Tenner A J. Cell surface expression of C1qRP/CD93 is stabilized by O-glycosylation[J]. J Cell Physiol,2003, 196(3):512-522.
[13] Chugh S, Barkeer S, Rachagani S,et al. Disruption of c1galt1 gene promotes development and metastasis of pancreatic adenocarcinomas in mice[J]. Gastroenterology,2018, 155(5):1608-1624.
[14] Ju T, Otto V I, Cummings R D.The Tn antigen-structural simplicity and biological complexity[J]. Angew Chem Int Ed Engl,2011, 50(8):1770-1791.
[15] Liu F, Fu J, Bergstrom K,et al. Core 1-derived mucin-type O-glycosylation protects against spontaneous gastritis and gastric cancer[J]. J Exp Med,2020, 217(1):e20182325
[16] Fu J, Wei B, Wen T,et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice[J]. J Clin Invest,2011, 121(4):1657-1666.
[17] Agarwal K, Kaul R, Garg M,et al. Inhibition of mucin-type O-glycosylation through metabolic processing and incorporation of N-thioglycolyl-D-galactosamine peracetate (Ac5 GalNTGc)[J]. J Am Chem Soc,2013, 135(38):14189-14197.
[18] Bergstrom K, Liu X, Zhao Y,et al. Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice[J]. Gastroenterology,2016, 151(1):152-164.e11.
[19] Kawashima H.Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer[J]. Biol Pharm Bull,2012, 35(10):1637-1641.
[20] Ju T, Cummings R D. Protein glycosylation:chaperone mutation in Tn syndrome[J]. Nature,2005, 437(7063):1252.
[21] Ju T, Lanneau G S, Gautam T,et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc[J]. Cancer Res,2008, 68(6):1636-1646.
[22] Wang Y, Ju T, Ding X,et al. Cosmc is an essential chaperone for correct protein O-glycosylation[J]. Proc Natl Acad Sci U S A,2010, 107(20):9228-9233.
[23] Jacobs B, De Roock W, Piessevaux H,et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab[J]. J Clin Oncol,2009, 27(30):5068-5074.
[24] Shirota Y, Stoehlmacher J, Brabender J,et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[J]. J Clin Oncol,2001, 19(23):4298-4304.
[25] Ogunkolade B W, Boucher B J, Fairclough P D,et al. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase mRNA in individuals with colorectal cancer[J]. Lancet,2002, 359(9320):1831-1832.
[26] Dekker E, Tanis P J, Vleugels J L A,et al. Colorectal cancer[J]. Lancet,2019, 394(10207):1467-1480.
[27] Keum N, Giovannucci E. Global burden of colorectal cancer:emerging trends, risk factors and prevention strategies[J]. Nat Rev Gastroenterol Hepatol,2019, 16(12):713-732.
[28] Sveen A, Kopetz S, Lothe R A. Biomarker-guided therapy for colorectal cancer:strength in complexity[J]. Nat Rev Clin Oncol,2020, 17(1):11-32.
[29] Fanelli G N, Dal Pozzo C A, Depetris I,et al. BrafThe heterogeneous clinical and pathological landscapes of metastatic-mutated colorectal cancer[J]. Cancer Cell Int,2020, 20:30.
[30] Kopetz S.New therapies and insights into the changing landscape of colorectal cancer[J]. Nat Rev Gastroenterol Hepatol,2019, 16(2):79-80.
[31] Matsuoka T, Yashiro M. Precision medicine for gastrointestinal cancer:Recent progress and future perspective[J]. World J Gastrointest Oncol,2020, 12(1):1-20.
[32] Tulchinsky E. Colorectal cancer cells use the negative feedback regulators of WNT signalling to activate epithelial-mesenchymal transition pathways[J]. Gut,2017, 66(4):563-564.
[33] Nakano M, Kikushige Y, Miyawaki K,et al. Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer[J]. Oncogene,2019, 38(6):780-793.
[34] Zhang J, Roberts T M, Shivdasani R A. Targeting PI3K signaling as a therapeutic approach for colorectal cancer[J]. Gastroenterology,2011, 141(1):50-61.
[35] Napolitano S, Matrone N, Muddassir A L,et al. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression[J]. J Exp Clin Cancer Res,2019, 38(1):492.
[36] Shahbazi S, Khorasani M, Mahdian R.Gene expression profile of FVII and AR in primary prostate cancer[J]. Cancer Biomark,2016, 17(3):353-358.
[37] Suzuki E, Sugimoto M, Kawaguchi K,et al. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients[J]. Breast Cancer,2019, 26(3):282-289.
[38] Lu W, Ding Z. Identification of key genes in prostate cancer gene expression profile by bioinformatics[J]. Andrologia,2019, 51(1):e13169.
[39] Liberelle M, Jonckheere N, Melnyk P, et al. EGF-containing membrane-bound mucins:a hidden ErbB2 targeting pathway?[J]. J Med Chem.(2020-02-13)[2020-02-13]. http://doi.org/10.1021/acs.jmedchem.9b02001.
[40] Mortezaee K. CXCL12/CXCR4 axis in the microenvironment of solid tumors:A critical mediator of metastasis[J]. Life Sci,2020, 249:117534.
[41] Stowell S R, Ju T, Cummings R D. Protein glycosylation in cancer[J]. Annu Rev Pathol,2015, 10:473-510.